Iconovo launches improved versions of nasal ICOone inhalers

Iconovo launches improved versions of nasal ICOone. Both inhalers are designed for high technical performance and to minimize the risk of user error. The development of the improved nasal ICOone inhalers has taken place within the framework of a successful development collaboration with Bill & Melinda Gates Foundation.

ICOone Nasal inhalers are the world’s only inhalation-driven nasal powder inhalers. The design of the improved versions of nasal ICOone inhalers are based on results from the successful user study conducted by Iconovo in 2022 and development work carried out at Iconovo and presented at the Respiratory Drug Delivery 2023 meeting.

We are proud to have been able to quickly develop our unique inhalation platforms for nasal powder administration that are suitable for vaccines as well as antiviral treatments and drugs that can offer a rapid systemic effect,” says Johan Wäborg, CEO of Iconovo.

To read full press release click here